PANDORA · Doctoral network on discovering pathomechanisms and novel drug optimization for AMD
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-10-01 → 2030-09-30
- Финансиране от ЕС
- 4 020 973 €
- Участници
- 16
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.
Накратко на български
Механизмите на имунната система в ретината се анализират, за да се разбере как те влияят върху енергийния обмен и стабилността на клетките при макулна дегенерация. Това помага за разработването на нови терапии и методи за проследяване на заболяването, което причинява слепота при възрастни.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
PANDORA will create a multidisciplinary, intersectoral European Doctoral Network focusing on complement system-mediated pathomechanisms and therapy development for Age-related macular degeneration (AMD). AMD, major cause of blindness in the elderly population, affects daily activities of ca. 200 million people worldwide, placing a major burden on national health systems and impairing patients’ quality of life. The complement system, known for its role in innate immune surveillance, is a major pathogenic driver in AMD, also involved in various other diseases, including sepsis, neurodegenerative, kidney, vascular diseases and cancer. We and others have recently demonstrated the importance of locally produced complement factors and non-canonical complement functions in the retina, affecting energy metabolism, protein degradation, mitochondrial stability, autophagy and lysophagy, which are found to be impaired in AMD. PANDORA will exploit state-of-the art model systems and techniques, including ex vivo multicellular, stem-cell derived and murine models, omics, imaging, biochemistry, histology, functional assays and computational modelling, to study in depth the different complement functions relevant to AMD and to find potential biomarkers for stratification and disease monitoring. PANDORA further aims to develop innovative therapeutic approaches, using gene therapy, compound screening, optimizing drug delivery to the retina, and a novel ultra-high resolution multimodality imaging system to monitor disease progression and treatment efficacy in vivo and in patients. PANDORA will train Doctoral Candidates as the next generation of European translational scientists in vision and medical research, and provides every student with the tools for a successful scientific career in academia or industry. Our multidisciplinary network offers a unique opportunity to expand the understanding and therapeutics for AMD in Europe, and to bring research findings to benefit for patients.
Оригинален текст от CORDIS (на английски).
Участници
- EBERHARD KARLS UNIVERSITAET TUEBINGEN · TuebingenКоординаторГермания
- BOEHRINGER INGELHEIM PHARMA GMBH &CO KG · IngelheimГермания
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisФранция
- FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA · Armilla GranadaИспания
- IDRYMA TECHNOLOGIAS KAI EREVNAS · IRAKLEIOГърция
- ITA-SUOMEN YLIOPISTO · KUOPIOФинландия
- KYMATONIKI IDIOTIKI KEFALAIOUCHIKI ETAIREIA · HeraklionГърция
- MICROFLUIDICS INNOVATION CENTER · PARISФранция
- PANEPISTIMIO KRITIS · RETHIMNOГърция
- Retina International CLG · Dublin 2Ниво градИрландия
- SORBONNE UNIVERSITE · ParisФранция
- THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinИрландия
- UNIVERSIDAD DE GRANADA · GranadaИспания
- UNIVERSITE DE FRIBOURG · FribourgШвейцария
- UNIVERSITE DE TOULOUSE · ToulouseФранция
- UNIVERSITY OF NEWCASTLE UPON TYNE · Newcastle Upon TyneОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз